Complement-mediated neutralisation identified in Ebola virus disease survivor plasma: Implications for protection and pathogenesis

It is well known that antibodies against the Ebola virus (EBOV) glycoprotein (GP) are associated with virus neutralization and disease development. However, the involvement of an additional immune factor such as complement to Ebola disease has not been studied in detail. Using EBOV convalescent plasma samples from 2013-2015 epidemic in West Africa (n = 206), the antibody-dependent complement deposition (ADCD) assay was performed. It was shown that the ADCD in response to EBOV GP was similar between samples that showed low and high neutralization titers, whereas that response to EBOV secretory GP was lower in the low neutralizing titer sample.